Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB - Get Free Report)'s stock price dropped 2.5% on Monday . The stock traded as low as $1.11 and last traded at $1.14. Approximately 82,547 shares were traded during trading, an increase of 45% from the average daily volume of 56,965 shares. The stock had previously closed at $1.17.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright initiated coverage on Connect Biopharma in a report on Thursday, June 12th. They set a "buy" rating and a $7.00 price objective on the stock.
Check Out Our Latest Analysis on CNTB
Connect Biopharma Price Performance
The stock's 50 day moving average price is $0.89 and its 200 day moving average price is $0.89. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.25 and a current ratio of 10.25.
Connect Biopharma (NASDAQ:CNTB - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. On average, sell-side analysts expect that Connect Biopharma Holdings Limited Sponsored ADR will post -0.22 earnings per share for the current fiscal year.
About Connect Biopharma
(
Get Free Report)
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Recommended Stories
Before you consider Connect Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Connect Biopharma wasn't on the list.
While Connect Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
